(ABUS) Presents Data from Combination Activity Studies of HBV Drug Candidates
Additional Preclinical Combination Data to be Presented This Year
Clinical Combination Studies to Begin in 2017
VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 22, 2016 — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentations this week by Dr. Michael Sofia, Arbutus’ Chief Scientific Officer, on results of several preclinical HBV drug combination studies at the 29th International Conference on Antiviral Research held April 17-21, and Cambridge Healthtech Institute’s 11th Annual Drug Discovery Chemistry conference held April 19-22, 2016, both in San Diego.
“We are excited to present this intriguing data from our preclinical drug combination studies. These data show additive or synergistic activity in in vitro and in vivo studies that evaluate different HBV disease markers such as cccDNA synthesis and expression, HBV rcDNA synthesis, HBsAg production and serum HBV DNA. We believe that combination therapy will enable an HBV cure with a finite treatment duration, and we have built a diverse pipeline of HBV product candidates at Arbutus to support this strategy,” said Dr. Sofia. “Our thorough preclinical evaluation of combinations of HBV candidates with different direct acting anti-viral mechanisms of action will inform our proprietary clinical combination studies, which will begin in 2017.”
These initial preclinical combination studies have established the following:
- Our drug candidates ARB-1467, AB-423, and AB-199 are potent and selective inhibitors of their respective targets.
- These drug candidates can be used in combination with the ‘nuc’ standard of care without any antagonism of drug activity.
- These drug candidates when used in combination with the ‘nuc’ standard of care demonstrate at least additive and in some cases synergistic activity.
- That our first proprietary drug combination, RNAi plus capsid formation inhibitor, also demonstrates additive activity.
- These results support Arbutus’ combination strategy.
Summary of the Studies Presented:
Combination | Study(ies) |
AB-423 (core protein/capsid inhibitor) with entecavir (EVT) | In vitro and in vivo |
AB-423 (core protein/capsid inhibitor) with ARB-1467 (RNAi) | In vitro and in vivo |
ARB-1467 (RNAi) with EVT | In vitro |
ARB-199 (cccDNA formation inhibitor) with EVT | In vitro |
ARB-199 (cccDNA formation inhibitor) with lamivudine | In vitro |
The presentation can be accessed by visiting the Investor sections of www.arbutusbio.com and selecting Events and Presentations.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection. Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements in this press release include statements about using a combination therapy to enable an HBV cure with a finite treatment duration; beginning proprietary clinical combination studies in 2017; the effectiveness of HBV candidates; and developing and commercializing a cure for patients suffering from chronic HBV infection using a three-pillar strategy.
With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of preclinical and clinical trials, and the usefulness of the data; the continued demand for Arbutus’ assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause Arbutus’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: anticipated pre-clinical and clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus’ products; economic and market conditions may worsen; and market shifts may require a change in strategic focus.
A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K and Arbutus’ continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604.419.3200 Email: acutler@arbutusbio.com Helia Baradarani Manager, Investor Relations Phone: 604.419.3200 Email: hbaradarani@arbutusbio.com Media Please direct all media inquiries to: media@arbutusbio.com
TraderPower Featured Companies
- Astrotech Corp. (NASDAQ: ASTC)
- Cepton Inc. (NASDAQ: CPTN)
- Clene Inc. (NASDAQ: CLNN)
- CNS Pharmaceuticals Inc. (NASDAQ: CNSP)
- Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)
- Freight Technologies Inc. (NASDAQ: FRGT)
- InMed Pharmaceuticals Inc. (NASDAQ: INM)
- Lexaria Bioscience Corp. (NASDAQ: LEXX)
- Mullen Automotive Inc. (NASDAQ: MULN)
- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)
Top Small Cap Market News
- $ASTC InvestorNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Launches ‘Gold Standard’ of Mass Spectrometry into Narcotics Detection Market
- $LEXX Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires Contract Research Organization to Perform Important GLP-1 Human Pilot Study
- $FNGR InvestorNewsBreaks – FingerMotion Inc. (NASDAQ: FNGR) Issues Capybara Research Litigation Update
- $QBTS InvestorNewsBreaks – The Register Interviews D-Wave Quantum Inc. (NYSE: QBTS), Highlights Quantum Computing’s Potential Impact on AI
- $BRVO Bravo Multinational Inc. (BRVO) Retains Seasoned Securities Lawyer to Assist in Uplisting Plans
- $GXRFF Texas Terminates $8.5B Investment in BlackRock, ESG Movement Stunned
- $SFWJ Software Effective Solutions Corp. (SFWJ) Completes Key Acquisitions, Is Committed to Becoming Cannabis Market Leader
- $VMAR Vision Marine Technologies Inc. (NASDAQ: VMAR) Helps Lead the Electric Boating Revolution, Establishes Partnership with Key Distributor
- $ZDPY Zoned Properties Inc. (ZDPY) Seizing Real Estate Opportunities in Growing Cannabis Industry
- $DLMI Diamond Lake Minerals Inc. (DLMI) Recognizes Tokenization As The Future of Financial Markets
- $GNPX InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering
- $NXPL InvestorNewsBreaks – NextPlat Corp. (NASDAQ: NXPL) Expands Technology E-Commerce Portfolio Through Strategic Acquisition
- $NXPL The Web3, Crypto, Blockchain, Metaverse Firms to Watch in 2024
- $NILA InvestorNewsBreaks – Nilam Resources Inc. (NILA) Signs LOI Marking ‘Significant Milestone,” Resulting in Acquisition of 24,800 Bitcoin
- $GTVH InvestorNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Announces Renewed Partnership with IBN for Corporate Communication Support
- $SUIC SUIC Worldwide Holdings Ltd. (SUIC) Is ‘One to Watch’
- $CIPI InvestorNewsBreaks – Correlate Energy Corp. (CIPI) Eyes Opportunity as Sun Seems to Shine on Solar
- $FRGT InvestorNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Announces Fourth-Quarter 2023 Preliminary Results Continue Revenue Growth Trend
- $SNES InvestorNewsBreaks – SenesTech Inc. (NASDAQ: SNES) Inks Distribution Deal with Wilco Distributing for Proprietary Pest-Management Products
- $SOBR InvestorNewsBreaks – SOBR Safe Inc. (NASDAQ: SOBR) Expands to Psychological Services and Therapy Sector
- $CLNN Clene Inc. (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS
- $ATBHF InvestorNewsBreaks – Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB:ATBHF), American West Metals Collaborate to Initiate Geophysical Program at Storm Copper Project
- $SFWJ 21 State AGs Urge Congress to Act on Hemp-Derived Intoxicants
Recent Posts
- $SFWJ 21 State AGs Urge Congress to Act on Hemp-Derived Intoxicants
- $ATBHF InvestorNewsBreaks – Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB:ATBHF), American West Metals Collaborate to Initiate Geophysical Program at Storm Copper Project
- $CLNN Clene Inc. (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS
- $SOBR InvestorNewsBreaks – SOBR Safe Inc. (NASDAQ: SOBR) Expands to Psychological Services and Therapy Sector
- $SNES InvestorNewsBreaks – SenesTech Inc. (NASDAQ: SNES) Inks Distribution Deal with Wilco Distributing for Proprietary Pest-Management Products
- $FRGT InvestorNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Announces Fourth-Quarter 2023 Preliminary Results Continue Revenue Growth Trend
- $CIPI InvestorNewsBreaks – Correlate Energy Corp. (CIPI) Eyes Opportunity as Sun Seems to Shine on Solar
- $SUIC SUIC Worldwide Holdings Ltd. (SUIC) Is ‘One to Watch’
Recent Comments
Archives
- March 2024
- January 2023
- June 2022
- December 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009